ADMA: Future Cash Returns And Label Expansion Will Support Share Upside

The updated analyst price target for ADMA Biologics moves from $30 to $20, as analysts factor in revised profit margin expectations, a higher discount rate, and a lower assumed future P/E multiple, even as revenue growth forecasts are adjusted.

Analyst Commentary

Recent Street research on ADMA Biologics shows a mix of caution and optimism, with some firms lowering price targets and others initiating coverage with a constructive view. While certain analysts have trimmed their expectations, bullish analysts are still highlighting potential upside based on the company’s execution and longer term growth story.

Bullish analysts pointing to upside potential are generally weighing revised assumptions on profit margins, discount rates, and valuation multiples against what they see as a still compelling core business. For you as an investor, the key takeaway is that even with lower headline targets, parts of the Street remain positive on the company’s ability to support its current valuation through fundamentals.

Bullish Takeaways

Bullish analysts initiating coverage with a positive view see room for the stock to reflect the company’s revenue profile and margin potential, even with more conservative P/E assumptions now in play.
Positive commentary in the initiation research highlights confidence in the company’s execution on its existing portfolio, which these analysts see as important support for the current valuation framework.
Some bullish views focus on the company’s ability to translate its revenue base into improved profitability over time, which they regard as a key catalyst for future rerating if delivered.
Where price targets are still set above current levels in these bullish reports, that stance is generally tied to expectations that the company can deliver on growth forecasts already laid out rather than relying on new, unproven drivers.

What's in the News

Multiple securities law firms, including Pomerantz LLP, Rosen Law Firm, Bleichmar Fonti & Auld LLP, Block & Leviton LLP, and Lowey Dannenberg, have opened investigations after a March 24, 2026 Culper Research report alleged ADMA Biologics inflated 2025 revenue growth by about 20% through channel stuffing of ASCENIV. The stock fell 29% over two trading days and further declined over 24% after the company withdrew long term financial guidance, according to recent legal and media reports.
ADMA Biologics reported Q1 2026 results showing flat total revenue year on year, 28% revenue growth for ASCENIV and a 54% revenue decline for BIVIGAM, 71% gross margins, a 22% rise in adjusted net income and 24% growth in adjusted EBITDA. The company updated full year 2026 revenue guidance to US$530 million to US$560 million while withdrawing long term guidance, based on the company’s earnings release coverage.
The company disclosed that three plasma centers were sold, generating an US$8 million gain, and that substantial share repurchases were funded with debt, including an accelerated share repurchase agreement with JPMorgan, according to Q1 2026 news reports.
ADMA Biologics received FDA approval to expand ASCENIV’s label to pediatric primary humoral immunodeficiency patients aged two years and older, following completion of a required post marketing pediatric assessment, as reported in company and FDA related announcements.
Following recent volatility and the reset to guidance, some covering analysts, including from Mizuho and Canaccord, kept favorable ratings with reduced price targets. Investment firm B Group increased its stake in ADMA Biologics, according to analyst and fund ownership reports.

Valuation Changes

Fair Value: revised down from $30.0 to $20.0, a reduction of one third in the modeled fair value estimate.
Discount Rate: increased slightly from 7.11% to 7.32%, implying a higher required return for valuing future cash flows.
Revenue Growth: adjusted modestly higher from 23.80% to 25.18%, reflecting a slightly stronger dollar revenue growth assumption.
Net Profit Margin: reduced from 43.87% to 39.92%, indicating a thinner dollar earnings margin assumption on future revenues.
Future P/E: lowered from 20.49x to 13.13x, signaling a more conservative valuation multiple applied to projected earnings.

13 views

Key Takeaways

Enhanced production processes and expanded plasma supply position the company for faster revenue growth and margin improvements beyond current market expectations.
Strong demand drivers, strategic investments, and financial flexibility support sustained market share gains and shareholder returns.
Heavy dependence on immunoglobulin therapies, cost pressures, and evolving competition threaten growth, margins, and long-term sustainability amid changing market and regulatory conditions.

Catalysts

About ADMA Biologics

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.What are the underlying business or industry changes driving this perspective?

While analyst consensus sees the yield enhancement process boosting output by 20 percent and driving mid
to long-term margin expansion, evidence from initial commercial-scale production suggests this increase could surpass 20 percent, providing even greater-than-expected improvements to both gross and net margins which are likely underappreciated in current financial guidance.
Analysts broadly agree that expanded plasma supply will be transformational for ASCENIV growth, but the ongoing record-setting high-titer plasma collection, alongside new facility investments enabling up to 30 percent manufacturing expansion, materially increases the likelihood that ADMA could establish a multibillion-dollar revenue business well ahead of consensus timelines, accelerating top-line revenue growth beyond current expectations.
The aging population and heightened global focus on immunological preparedness post-pandemic are catalyzing long-term demand for immune globulins, and ADMA's fully U.S.-based, vertically integrated model positions it as a preferred supplier for large-scale, stable purchasing contracts, underpinning both revenue resilience and margin durability for years to come.
The anticipated release of health economics data demonstrating ASCENIV's ability to reduce hospitalizations and total healthcare expenditures will not only drive faster physician adoption but also enable premium pricing and stronger payer reimbursement, accelerating both market share gains and average selling price, directly boosting revenues and net margins.
With the newly secured, lower-cost $300 million credit facility and a $500 million share repurchase program underway, ADMA can leverage capital markets opportunistically, using free cash flow to both expand operations during industry up-cycles and aggressively buy back stock, delivering substantial EPS accretion and returns to shareholders in addition to core operating earnings growth.

ADMA Biologics Earnings and Revenue Growth

ADMA Biologics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on ADMA Biologics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming ADMA Biologics's revenue will grow by 25.2% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from 32.4% today to 39.9% in 3 years time.
The bullish analysts expect earnings to reach $399.2 million (and earnings per share of $1.64) by about June 2029, up from $165.4 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $325.1 million.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 13.2x on those 2029 earnings, up from 11.1x today. This future PE is lower than the current PE for the US Biotechs industry at 16.2x.
The bullish analysts expect the number of shares outstanding to decline by 2.87% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.32%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

ADMA's heavy reliance on a narrow product portfolio, predominantly its immunoglobulin therapies like ASCENIV, exposes the company to significant risk from adverse regulatory changes, payer pushback on reimbursement, or clinical setbacks, any of which could destabilize revenues over the long run.
Secular trends toward rising healthcare cost containment and more stringent payer scrutiny could erode realized pricing for plasma-derived products, pressuring future revenue growth and contributing to net margin compression if payers implement tighter reimbursement for ASCENIV and similar therapies.
Increasing global competition for plasma as a raw material, combined with the potential for higher input costs and supply chain constraints, threatens to drive up manufacturing expenses for ADMA and impede its ability to deliver gross margin expansion as forecasted.
Advances in alternative therapeutic modalities, such as synthetic biologics, gene therapies, or new small molecule treatments, could gradually reduce market demand for plasma-based immunoglobulins, challenging ADMA's long-term earnings and revenue outlook as newer therapies become standard-of-care.
The company's ongoing investments in infrastructure and plasma collection create substantial fixed cost obligations, which may not scale efficiently with evolving market realities or competitive dynamics, increasing the risk of persistent operating leverage challenges that would erode operating income and free cash flow.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for ADMA Biologics is $20.0, which represents up to two standard deviations above the consensus price target of $16.75. This valuation is based on what can be assumed as the expectations of ADMA Biologics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $1.0 billion, earnings will come to $399.2 million, and it would be trading on a PE ratio of 13.2x, assuming you use a discount rate of 7.3%.
Given the current share price of $7.9, the analyst price target of $20.0 is 60.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on ADMA Biologics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Population And Plasma Supply Will Drive Industry Expansion